Advertisement

Digestive Diseases and Sciences

, Volume 58, Issue 4, pp 1010–1015 | Cite as

Detection of TFPI2 Methylation in the Serum of Hepatocellular Carcinoma Patients

  • Feng-Kai Sun
  • Yu-Chen Fan
  • Jing Zhao
  • Feng Zhang
  • Shuai Gao
  • Ze-Hua Zhao
  • Qi Sun
  • Kai Wang
Original Article

Abstract

Background

DNA methylation plays a key role in hepatocellular carcinogenesis and progression. Analysis of aberrant methylation in serum DNA might provide a strategy for noninvasive detection of hepatocellular carcinoma (HCC).

Methods

To explore the feasibility of this approach, we compared TFPI2 methylation status in serum samples of HCC, chronic hepatitis B (CHB) patients and normal control groups using methylation-specific polymerase chain reaction.

Results

Our results showed that the percentage of serum TFPI2 promoter methylation was significantly higher in the HCC group (46.5 %, 20/43) compared with the CHB group (16.7 %, 4/24; p = 0.015) and the normal control group (19.2 %, 5/26; p = 0.022), respectively, indicating that TFPI2 methylation frequently existed in the serum of HCC patients. In our study, the detection rate of HCC using serum TFPI2 methylation was 46.5 % (20/43), which was quite close to the reported detection rate of α-fetoprotein (54 %). In cases where we combined both markers, the detection rate was 61.0 %, suggesting that serum TFPI2 methylation could be used as a potential marker for noninvasive detection of HCC. Then, we evaluated the correlation between the serum TFPI2 methylation status of HCC patients and their clinicopathological parameters. Patients with advanced TNM stage (III–IV) showed a significantly elevated serum methylation percentage of TFPI2 in comparison with those with early TNM stage (I–II) (p = 0.025). Moreover, TFPI2 methylation was observed more frequently according to the progression of TNM stage.

Conclusions

Our present study suggested that TFPI2 methylation in serum tended to be detected more easily in patients with advanced HCC and might be used as a predictor of HCC progression.

Keywords

TFPI2 Methylation Serum Hepatocellular carcinoma 

Abbreviations

AASLD

American Association for the Study of Liver Diseases

AFP

α-Fetoprotein

cfDNA

Circulating cell-free DNA

CHB

Chronic hepatitis B

ECM

Extracellular matrix

HBV

Hepatitis B virus

HCC

Hepatocellular carcinoma

MMPs

Matrix metalloproteinases

MSP

Methylation-specific polymerase chain reaction

TFPI2

Tissue factor pathway inhibitor-2

US

Ultrasonography

Notes

Acknowledgments

This work was supported by grants from the National Key Technology R&D Program (2011BAZ03191), Key Project of Chinese Ministry of Science and Technology (2012ZX10002007), National Natural Science Foundation of China (81171579,81201287), Natural Science Foundation of Shandong Province (ZR2010HM070, ZR2010HQ040), Independent Innovation Foundation of Shandong University (IIFSDU, 2010TS013), and Science and Technology Development Plan Project of Shandong Province (2012GGE27053).

Conflict of interest

None.

References

  1. 1.
    Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379:1245–1255.PubMedCrossRefGoogle Scholar
  2. 2.
    Farinati F, Marino D, De Giorgio M, et al. Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither? Am J Gastroenterol. 2006;101:524–532.PubMedCrossRefGoogle Scholar
  3. 3.
    El-Serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology. 2008;134:1752–1763.PubMedCrossRefGoogle Scholar
  4. 4.
    Fleischhacker M, Schmidt B. Circulating nucleic acids (CNAs) and cancer—a survey. Biochim Biophys Acta. 2007;1775:181–232.PubMedGoogle Scholar
  5. 5.
    Leon SA, Shapiro B, Sklaroff DM, Yaros MJ. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 1977;37:646–650.PubMedGoogle Scholar
  6. 6.
    Hanash SM, Baik CS, Kallioniemi O. Emerging molecular biomarkers—blood-based strategies to detect and monitor cancer. Nat Rev Clin Oncol. 2011;8:142–150.PubMedCrossRefGoogle Scholar
  7. 7.
    Kohler C, Barekati Z, Radpour R, Zhong XY. Cell-free DNA in the circulation as a potential cancer biomarker. Anticancer Res. 2011;31:2623–2628.PubMedGoogle Scholar
  8. 8.
    Huang Z, Hua D, Hu Y, et al. Quantitation of plasma circulating DNA using quantitative PCR for the detection of hepatocellular carcinoma. Pathol Oncol Res. 2012;18:271–276.PubMedCrossRefGoogle Scholar
  9. 9.
    Schwarzenbach H, Hoon DS, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer. 2011;11:426–437.PubMedCrossRefGoogle Scholar
  10. 10.
    Wong IH, Lo YM, Zhang J, et al. Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients. Cancer Res. 1999;59:71–73.PubMedGoogle Scholar
  11. 11.
    Zhang YJ, Wu HC, Shen J, et al. Predicting hepatocellular carcinoma by detection of aberrant promoter methylation in serum DNA. Clin Cancer Res. 2007;13:2378–2384.PubMedCrossRefGoogle Scholar
  12. 12.
    Wong IH, Lo YM, Yeo W, Lau WY, Johnson PJ. Frequent p15 promoter methylation in tumor and peripheral blood from hepatocellular carcinoma patients. Clin Cancer Res. 2000;6:3516–3521.PubMedGoogle Scholar
  13. 13.
    Wang J, Qin Y, Li B, Sun Z, Yang B. Detection of aberrant promoter methylation of GSTP1 in the tumor and serum of Chinese human primary hepatocellular carcinoma patients. Clin Biochem. 2006;39:344–348.PubMedCrossRefGoogle Scholar
  14. 14.
    Huang ZH, Hu Y, Hua D, Wu YY, Song MX, Cheng ZH. Quantitative analysis of multiple methylated genes in plasma for the diagnosis and prognosis of hepatocellular carcinoma. Exp Mol Pathol. 2011;91:702–707.PubMedCrossRefGoogle Scholar
  15. 15.
    Chan KC, Lai PB, Mok TS, et al. Quantitative analysis of circulating methylated DNA as a biomarker for hepatocellular carcinoma. Clin Chem. 2008;54:1528–1536.PubMedCrossRefGoogle Scholar
  16. 16.
    Rao CN, Liu YY, Peavey CL, Woodley DT. Novel extracellular matrix-associated serine proteinase inhibitors from human skin fibroblasts. Arch Biochem Biophys. 1995;317:311–314.PubMedCrossRefGoogle Scholar
  17. 17.
    Sprecher CA, Kisiel W, Mathewes S, Foster DC. Molecular cloning, expression, and partial characterization of a second human tissue-factor-pathway inhibitor. Proc Natl Acad Sci USA. 1994;91:3353–3357.PubMedCrossRefGoogle Scholar
  18. 18.
    Rao CN, Mohanam S, Puppala A, Rao JS. Regulation of ProMMP-1 and ProMMP-3 activation by tissue factor pathway inhibitor-2/matrix-associated serine protease inhibitor. Biochem Biophys Res Commun. 1999;255:94–98.PubMedCrossRefGoogle Scholar
  19. 19.
    Hibi K, Goto T, Kitamura YH, et al. Methylation of TFPI2 gene is frequently detected in advanced well-differentiated colorectal cancer. Anticancer Res. 2010;30:1205–1207.PubMedGoogle Scholar
  20. 20.
    Hibi K, Goto T, Shirahata A, et al. Detection of TFPI2 methylation in the serum of colorectal cancer patients. Cancer Lett. 2011;311:96–100.PubMedCrossRefGoogle Scholar
  21. 21.
    Wong CM, Ng YL, Lee JM, et al. Tissue factor pathway inhibitor-2 as a frequently silenced tumor suppressor gene in hepatocellular carcinoma. Hepatology. 2007;45:1129–1138.PubMedCrossRefGoogle Scholar
  22. 22.
    Bruix J, Sherman M, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020–1022.PubMedCrossRefGoogle Scholar
  23. 23.
    Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50:661–662.PubMedCrossRefGoogle Scholar
  24. 24.
    Hibi K, Goto T, Shirahata A, et al. Detection of TFPI2 methylation in the serum of gastric cancer patients. Anticancer Res. 2011;31:3835–3838.PubMedGoogle Scholar
  25. 25.
    Yanamandra N, Kondraganti S, Gondi CS, et al. Recombinant adeno-associated virus (rAAV) expressing TFPI-2 inhibits invasion, angiogenesis and tumor growth in a human glioblastoma cell line. Int J Cancer. 2005;115:998–1005.PubMedCrossRefGoogle Scholar
  26. 26.
    Blindt R, Vogt F, Lamby D, et al. Characterization of differential gene expression in quiescent and invasive human arterial smooth muscle cells. J Vasc Res. 2002;39:340–352.PubMedCrossRefGoogle Scholar
  27. 27.
    Liu Y, Stack SM, Lakka SS, et al. Matrix localization of tissue factor pathway inhibitor-2/matrix-associated serine protease inhibitor (TFPI-2/MSPI) involves arginine-mediated ionic interactions with heparin and dermatan sulfate: heparin accelerates the activity of TFPI-2/MSPI toward plasmin. Arch Biochem Biophys. 1999;370:112–118.PubMedCrossRefGoogle Scholar
  28. 28.
    George J, Gondi CS, Dinh DH, Gujrati M, Rao JS. Restoration of tissue factor pathway inhibitor-2 in a human glioblastoma cell line triggers caspase-mediated pathway and apoptosis. Clin Cancer Res. 2007;13:3507–3517.PubMedCrossRefGoogle Scholar
  29. 29.
    Sato N, Parker AR, Fukushima N, et al. Epigenetic inactivation of TFPI-2 as a common mechanism associated with growth and invasion of pancreatic ductal adenocarcinoma. Oncogene. 2005;24:850–858.PubMedCrossRefGoogle Scholar
  30. 30.
    Konduri SD, Rao CN, Chandrasekar N, et al. A novel function of tissue factor pathway inhibitor-2 (TFPI-2) in human glioma invasion. Oncogene. 2001;20:6938–6945.PubMedCrossRefGoogle Scholar
  31. 31.
    Konduri SD, Tasiou A, Chandrasekar N, Rao JS. Overexpression of tissue factor pathway inhibitor-2 (TFPI-2), decreases the invasiveness of prostate cancer cells in vitro. Int J Oncol. 2001;18:127–131.PubMedGoogle Scholar
  32. 32.
    Rollin J, Iochmann S, Bléchet C, et al. Expression and methylation status of tissue factor pathway inhibitor-2 gene in non-small-cell lung cancer. Br J Cancer. 2005;92:775–783.PubMedCrossRefGoogle Scholar
  33. 33.
    Jiang P, Watanabe H, Okada G, et al. Diagnostic utility of aberrant methylation of tissue factor pathway inhibitor 2 in pure pancreatic juice for pancreatic carcinoma. Cancer Sci. 2006;97:1267–1273.PubMedCrossRefGoogle Scholar
  34. 34.
    Vogelstein B, Kinzler KW. Digital PCR. Proc Natl Acad Sci USA. 1999;96:9236–9241.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2012

Authors and Affiliations

  • Feng-Kai Sun
    • 1
  • Yu-Chen Fan
    • 1
    • 2
  • Jing Zhao
    • 1
  • Feng Zhang
    • 1
  • Shuai Gao
    • 1
  • Ze-Hua Zhao
    • 1
  • Qi Sun
    • 3
  • Kai Wang
    • 1
    • 2
  1. 1.Department of HepatologyQilu Hospital of Shandong UniversityJinanChina
  2. 2.Institute of HepatologyShandong UniversityJinanChina
  3. 3.Department of Hepatobiliary SurgeryQilu Hospital of Shandong UniversityJinanChina

Personalised recommendations